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Abstract
Background: Although gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the
gastrointestinal tract, they comprise less than 1% of all gastrointestinal tumors. Neuroendocrine tumors (NET) of the
gastro-enteropancreatic system are also rare, representing about 2% of all gastrointestinal neoplasms. Pancreatic
localization of NET is extremely uncommon—these tumors are only 1–5% of all pancreatic cancers.
Case presentation: We describe an unusual case with triple tumor localization—a gastric tumor, a formation in the
pancreas, which involves the retroperitoneal space, and a uterine leiomyoma. The exact diagnosis was confirmed
with immunohistochemical study after surgical treatment of the patient. Distal pancreatic resection, splenectomy,
partial gastrectomy, omentectomy, and hysterectomy were performed. The histological examination proved an
epithelioid type of gastric GIST. Immunostaining showed focal positive expression of c-kit and no mitotic figures per
50 HPF. Histology of the pancreatic and retroperitoneal formation proved a well-differentiated NET with origin from
the islets of Langerhans. The immunohistochemical study demonstrated co-expression of chromogranin A and
synaptophysin.
Conclusions: This is the fourth case published so far of a patient with synchronous pancreatic NET and gastric GIST.
The main objective of the study is to present a unique case because we have not found any reports for
coexistence of the described three types of neoplasm, as in our patient, and we hope that it will be valuable in the
future investigations about the genesis, diagnosis, and treatment of these types of tumors.
Keywords: Pancreatic neuroendocrine tumor, Gastrointestinal stromal tumor, Uterine leiomyoma, Chromogranin A,
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Background
Although gastrointestinal stromal tumors (GISTs) are
the most common mesenchymal tumors of the gastro-
intestinal (GI) tract, they comprise less than 1% of all GI
tumors [1]. Their annual incidence is 11–19.6 cases per
100,000 individuals [2, 3]. Neuroendocrine tumors
(NETs) of the gastro-enteropancreatic (GEP) system are
also rare, usually sporadic, representing about 2% of all
GI tumors [4]. Pancreatic localization of NETs is ex-
tremely uncommon—these neoplasms are only 1–5% of
all the pancreatic cancers and their incidence does not
exceed five to one million [4]. On the other hand, uter-
ine fibroids (also known as leiomyomas or myomas) are
the commonest benign uterine tumors associated with
significant morbidity to nearly 40% of women during
their reproductive years and sometimes even after
menopause [5]. Because the coexistence of the described
three tumors is quite unusual and unique, we present
the details of our case. We used the collected data about
the patient from the medical records in our hospital and
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from the available medical documentation of her previ-
ous hospital stays and medical treatment.
Case presentation
A 60-year-old female was admitted with symptoms of
weakness and single occurrence of black and tarry
stools. The patient’s co-morbidities included arterial
hypertension and diabetes. A uterine myoma had been
diagnosed a few years ago. Familial disease history in-
cluded a mother with arterial hypertension and diabetes,
died of heart attack, and a father, died of a stroke. Her
aunt died of a gastric cancer.
The physical examination revealed that the abdomen
was respiratory movable, without palpable pain, but with
two palpable formations with dense texture. The first
formation was movable and localized in the epigastrium,
measuring about 7 cm. Under the umbilical horizontal,
there was an immobile tumor with smooth surface and
about 25 cm in size. The rectal digital examination did
not establish presence of melena.
The ultrasound revealed a soft tissue formation with
heterogeneous structure, located in epigastric region and
infiltrating the liver. Endoscopic examination showed a
small duodenal ulcerative lesion. Because of this, abdom-
inal computed tomography (CT) was performed. It dem-
onstrated a heterodense formation, localized in the
retroperitoneal space, under the liver, without infiltration
of it. The tumor was about 70 mm and had smooth and
sharp outlines (Fig. 1a). There was another formation in
the pelvis with similar features, but 143/124 mm in size.
The uterus was behind it with suspected infiltration of
the organ (Fig. 1b). The results from routine laboratory
tests were within normal limits. The exact diagnosis was
confirmed with immunohistochemical study after surgi-
cal treatment of the patient.
The intraoperative exploration revealed an enlarged
uterus, involved by a huge fibroid, measuring more than
20 cm. There was a tumor formation, involving the front
gastric wall in the pyloric area, which was with irregular
shape, dense texture, and diameter about 6–7 cm. A sec-
ond tumor, measuring about 7 cm, was detected in the
retroperitoneal space. The formation was connected to
another tumor in the pancreatic body, which was about
5 cm in size. The tumors were with solid consistency
and oval shape and did not involve other organs and
tissues.
Splenectomy and distal pancreatic resection was per-
formed, and the retroperitoneal tumor was carefully ex-
tirpated. Because of the presence of gastric tumor, a
Billroth’s operation II and omentectomy were carried
out. The surgical procedure ended with hysterectomy,
considering the large uterine myoma.
The gross pathological evaluation revealed a well-
demarcated gastric tumor, just beneath a hyperemic mu-
cosa, extending through the gastric wall to the grossly
unremarkable serous. Cut surfice showed central cavity.
The histological examination proved an epithelioid type
of gastric GIST. Immunostaining showed focal positive
expression of c-kit (CD117). No mitotic figures were
found per 50 HPF (10 mm2), subsequently confirmed by
immunohistochemical examination with Ki-67 (Fig. 2a
and b). The patient has refused the investigation of the
GIST mutational status KIT/PDGFRA.
The retroperitoneal tumor was firm and encapsulated,
with cut surface, variegated with small cystic and
hemorrhagic areas. Histology proved a well-differentiated
NET with origin from the islets of Langerhans. Immuno-
histochemical tumor cells demonstrated co-expression of
chromogranin A and synaptophysin. Tumor proliferative
activity, as estimated by Ki-67, was low—there was
intensive nuclear expression in 1 to 2% of tumor cells
(Fig. 2c, d, e).
Specimen from the pancreas contained a well-
delineated firm tumor with heterogenous cut surface
and unremarkable spleen. Microscopically, tumor tissue
was proved identical to the retroperitoneal one.
Lastly, microscopic examination of the signifiacantly
enlarged uterus found a leiomyoma without further
qualifiers (Fig. 2f ).
Postoperative period was uneventful. Octreoscan
showed no evidence of metastatic focus, and because of
the low risk of progression of GIST, according to
Fig. 1 a CT image of retroperitoneal tumor located under the liver. b CT image of pelvic formation
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Miettinen’s classification, the patient did not carry out
any additional treatment. A regular follow-up was per-
formed. Six years after the operation, the patient was in
good health without clinical, ultrasound, and CT im-
aging data for the recurrent disease.
The present study involved a literature search for rele-
vant articles using Pubmed and Web of Science. To
minimize the chance of missing an important study, a
manual search of the references of all articles found in
our search was also performed. The keywords were as
follows: “neuroendocrine tumors,” “leiomyoma,” and
“gastrointestinal stromal tumors.” GISTs are rare, usually
sporadic neoplasms arising from, or differentiating
along, a line similar to the interstitial cells of Cajal [1].
These neoplasms most commonly occur in the stomach
(60–70%), followed by the small intestine (20–30%),
duodenum (4–5%), rectum (4–5%), colon (<2%), and
esophagus(<1%) [1, 6]. Gastric GISTs can be incidentally
detected or usually manifested with non-specific symp-
toms, such as nausea, vomiting, and abdominal pain or,
most often, with bleeding, [4] as in our case. Pathologic
diagnosis is based on both unique microscopic features
(fusiform, epithelioid or mixed type) and immunohis-
tochemical techniques (CD-117, CD34, actin, desmin,
S-100, and Ki-67) with counting of the number of
mitoses per 50 HPF [1, 7, 8]. Different types of muta-
tions can be found in KIT and PDGFRA genes encod-
ing a receptor tyrosine kinases type III (RTC). Risk
stratification of GISTs according to Miettinen et al.,
Fletcher’s classification and UICC classification is based
on tumor size, mitotic index, and localization of the tumor
[1, 6–8]. Achieved resection margins (R0 or R1) and
Fig. 2 Histology. a Microscopic section of the gastric GIST (H&E ×200). b Immunohistochemical reaction for c-kit (×400). c Microscopic section of
the pancreatic NET (H&E ×100). d Immunohistochemical reaction for chromogranin A (×400). e Immunohistochemical reaction for synaptophysin
(×400). f Microscopic section of the leiomyoma of the uterus (H&E ×200)
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capsule rupture are other prognostic factors [8]. The
standard treatment of GISTs is surgical resection [1, 7, 8].
Targeted medical therapy by tyrosine kinase inhibitors is
recommended only for GIST that is marginally resectable
or resectable with a risk of significant morbidity [4, 7, 9].
Pancreatic NETs are also uncommon neoplasms which
originate from diffuse neuroendocrine cells [4]. Pancre-
atic NETs may be divided into functional (F-pancreatic
NET) and non-functional (NF-pancreatic NET), depend-
ing on their ability to secrete biologically active
hormones [10]. Because of this, as in our case, the NF-
pancreatic NETs can be asymptomatic before they reach
a significant tumor size when the symptoms are result
from the mass effect and involvement of the adjacent or-
gans [10]. Therefore, diagnosis of NF-pancreatic NETs
depends on detailed biochemical, radiographic, and
pathologic examination [10]. The histopathological and
immunohistochemical (chromogranin A and synapto-
physin) examinations play an essential role in establish-
ing the diagnosis and prognosis of a neuroendocrine
tumor [11]. By WHO classification, G1 tumors have a
variable structure, either with insular, trabecular, acinar,
diffuse or mixed patterns, and by a monomorphic cy-
tology with low atypia and rare if any mitosis (<2/
10 HPF), Ki-67 <2% [4, 10]. G2 tumors show focal mod-
erate cytological atypia with a few scattered mitotic fig-
ures (2–20/10 HPF), Ki-67 3-20%, and spotty necrosis
[4, 10]. G3 tumors demonstrate a solid growth pattern;
the tumor cells are small, round or oat cell-like with
marked nuclear pleomorphism, brisk mitotic activity
(>20/10 HPF), Ki-67 >20%, and sizeable areas of tumor
necrosis [4, 10]. In our case, the pancreatic NET was de-
termined as G1.
GISTs have been described to coexist with other neo-
plasms, the percentage of such cases ranging from 4.5 to
33% [4]. They frequently develop as a result of heredi-
tary diseases, such as neurofibromatosis type 1 (NF1),
Carney’s triad (GIST, paraganglioma and pulmonary
chondroma), Carney’s dyad (paraganglioma and gastric
GIST), and familial GIST [3]. On the other hand, GEP
NETs may be related to increased risk of synchronous
malignancies [4]. That can be the result from the fact
that 10% of NETs will be associated with an inherited
genetic syndromes, such as MEN1 (hyperparathyroidism,
pancreatic NETs in up to 75% of cases, and pituitary tu-
mors), Von Hippel-Lindau disease (NF-pancreatic NETs)
in 10–20% of patients, cystadenomas, hemangioblasto-
mas and adenocarcinoma, tuberous sclerosis, and NF1
[10]. The coexistence of gastric GIST and pancreatic
NETs is extremely a rare condition and there are only
three more cases, described in the literature, excluding
our case [4, 12, 13]. Although there are very few cases of
NF1-related concurrent GEP NETs and GISTs, there is
no evidence that the mutation in the NF1 involved in
the pathogenesis of GIST is the same mutation existing
in NF1 patients with coexistent GISTs and GEP NETs
[12]. In the described four cases (with our patient), there
was also no family history or clinical findings suggestive
of NF-1, so mutations in non-NF1 patients with coexist-
ent GISTs and GEP NETs are still unclear. Interestingly,
in the three cases with synchronous gastric GIST and
pancreatic NETs, as in our case, the grade of GIST is
low or very low, and the pancreatic NETs are non-
functional in three of the four cases [4, 12, 13].
Although uterine leiomyomas are the commonest be-
nign uterine tumors [5], the coexistence with pancreatic
NETs and gastric GIST is quite unusual and we believe
that our patient is the first described case with such a
tumor combination. Pathogenesis of uterine leiomyomas
is not clearly known, too. Mechanotransduction, the re-
sponse of cells to the mechanical forces such as com-
pression and stretch and steroid-dependent growth are
some of the mechanisms of occurrence of leiomyomas
[5, 14]. There are some studies that revealed genetic
alterations in patients with uterine leiomyomas—a
chromosomal rearrangement of 12q14-15 reflecting the
rearrangement of the HMGA2 allele and a mutation of
mediator complex subunit 12 (MED12), a transcription
factor gene [14, 15]. However, not all patients with leio-
myomas display these genetic alterations [14, 15], and
there are no evidence that these mutations have relation
to the occurrence of pancreatic NETs and GIST. The
limitations of our study are related to the patient’s re-
fusal for performance of genetic investigations, so we
could not prove a specific genetic disorder that may pro-
voke the concomitant appearance of these neoplasms.
However, we hope the presentation of this case could be
useful in future studies about the genesis, diagnosis, and
treatment of these types of tumors and correlations be-
tween them.
Conclusions
We describe an unusual case with triple tumor
localization—gastric GIST, pancreatic NET, and uterine
leiomyoma. We have not found any reports for coexist-
ence of the described three types of tumors, which makes
our case interesting, unique, and valuable.
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